• Taysha Gene Therapies published safety and efficacy results from REVEAL Part A Phase 1/2 trial of TSHA-102 in Rett syndrome.
• As of a May 2026 data cut, 12 patients aged 6-21 received TSHA-102 across low dose (N=4) and high dose (N=8).
• No treatment-related serious adverse events or dose-limiting toxicities were reported; related events were mild-to-moderate, led by elevated liver enzymes (33%).
• Response rate for gaining or regaining at least one developmental milestone was 83% at 6 months, rising to 100% at 12 months.
• Management highlighted the dataset as exceeding an FDA-aligned efficacy threshold, supporting a potential BLA filing tied to a 6-month pivotal interim analysis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.